|
Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials. |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche |
Research Funding - Jiangsu Hengrui Medicine (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Jiangsu Hengrui Medicine |
|
|
Employment - Jiangsu Hengrui Medicine |
|
|
Employment - Jiangsu Hengrui Medicine |
|
|
No Relationships to Disclose |